Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment

被引：681
作者：
Goldman, JM [1 ]
Melo, JV [1 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Haematol, London SW7 2AZ, England
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2003年 / 349卷 / 15期
关键词：
D O I：
10.1056/NEJMra020777
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1451 / 1464
页数：14
相关论文
共 137 条
[1]   Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].
Azam, M ;
Latek, RR ;
Daley, GQ .
CELL, 2003, 112 (06) :831-843
[2]   A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia [J].
Baccarani, M ;
Rosti, G ;
de Vivo, A ;
Bonifazi, F ;
Russo, D ;
Martinelli, G ;
Testoni, N ;
Amabile, M ;
Fiacchini, M ;
Montefusco, E ;
Saglio, G ;
Tura, S .
BLOOD, 2002, 99 (05) :1527-1535
[3]   Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia [J].
Barnes, DJ ;
Melo, JV .
ACTA HAEMATOLOGICA, 2002, 108 (04) :180-202
[4]   Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies [J].
Barrett, AJ ;
Malkovska, V .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (04) :754-761
[5]   Allogeneic stem cell transplantation for chronic myeloid leukemia [J].
Barrett, J .
SEMINARS IN HEMATOLOGY, 2003, 40 (01) :59-71
[6]  
BEDI A, 1994, BLOOD, V83, P2038
[7]   Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells [J].
Bhat, A ;
Kolibaba, K ;
Oda, T ;
OhnoJones, S ;
Heaney, C ;
Druker, BJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (26) :16170-16175
[8]  
BIERNAUX C, 1995, BLOOD, V86, P3118
[9]   The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease [J].
Bose, S ;
Deininger, M ;
Gora-Tybor, J ;
Goldman, JM ;
Melo, JV .
BLOOD, 1998, 92 (09) :3362-3367
[10]   High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Grigg, A ;
Arthur, C ;
Taylor, K ;
Herrmann, R ;
Lynch, KP ;
Hughes, TP .
BLOOD, 2002, 99 (09) :3472-3475
12345678910